SGEN - Seattle Genetics, Inc.
72.38 0.00 (0.00%)
After hours: 4:47PM EDT
| Previous Close | 73.14 |
| Open | 73.31 |
| Bid | 62.28 x 1800 |
| Ask | 79.45 x 800 |
| Day's Range | 71.78 - 73.64 |
| 52 Week Range | 50.71 - 84.37 |
| Volume | 335,308 |
| Avg. Volume | 832,039 |
| Market Cap | 11.676B |
| Beta (3Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.78 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 79.46 |
- Markit•yesterday
See what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 29. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding SGEN are favorable, with net inflows of $4.83 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•yesterday
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
- Simply Wall St.•2 days ago
Does Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Salary Compare Well With Others?
Clay Siegall became the CEO of Seattle Genetics, Inc. (NASDAQ:SGEN) in 2002. This analysis aims first to contrast CEO...
- Business Wire•7 days ago
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML)
-Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers-
- Zacks•8 days ago
Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.
- Business Wire•9 days ago
Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
Seattle Genetics, Inc. (SGEN) today announced U.S. Food and Drug Administration (FDA) approval of Polivy™ (polatuzumab vedotin-piiq), which is an antibody-drug conjugate (ADC) targeting CD79b that utilizes Seattle Genetics’ technology. Polivy was developed and will be commercialized by Genentech, a member of the Roche Group. Polivy previously received FDA Breakthrough Therapy Designation, and was approved more than two months ahead of the Prescription Drug User Fee Act (PDUFA) action date of August 19, 2019.
- Zacks•15 days ago
Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.
- Investor's Business Daily•16 days ago
Who Are The Winners And Losers From The Year's Biggest Cancer Meeting?
Biotech stocks jumped Monday with Nektar Therapeutics, Iovance Therapeutics and Seattle Genetics stocks among the market leaders. All three rose on promising studies in cancer treatment.
- Reuters•16 days ago
Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study
An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday. Seattle Genetics shares rose 4.3% to $67.84. Responses were similar even among patients with the worst prognosis, including those whose cancer had spread to the liver, patients who had received three or more previous therapies and those who did not respond to treatment with an immuno-oncology drug, such as Merck & Co's Keytruda, researchers reported.
- Reuters•16 days ago
Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study
An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday. Responses were similar even among patients with the worst prognosis, including those whose cancer had spread to the liver, patients who had received three or more previous therapies and those who did not respond to treatment with an immuno-oncology drug, such as Merck & Co's Keytruda, researchers reported.
- Business Wire•16 days ago
Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting
Three-Year Update of ECHELON-1 Trial Continues to Demonstrate Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Hodgkin Lym
- PR Newswire•16 days ago
Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor- -Data Featured ...
- Business Wire•16 days ago
Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1
- Benzinga•18 days ago
The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding ...
- American City Business Journals•20 days ago
Revealed: PSBJ inaugural Middle Market Fast 50 list makers
The companies on this list are a mix of public and private, and had revenue between $25 million and $1 billion in 2018. Together, they brought in $16.6 billion in revenue last year and employed more than 15,250 in the state and nearly 47,000 globally.
- Zacks•25 days ago
Seattle Genetics (SGEN) Down 2.7% Since Last Earnings Report: Can It Rebound?
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•29 days ago
Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer
Seattle Genetics, Inc. today announced the appointment of Robin G. Taylor, M.B.A., Ph.D., as Chief Commercial Officer. Dr. Taylor brings 18 years of biotechnology and pharmaceutical company experience in the commercialization of oncology drugs, including significant marketing, launch and global product strategy roles at both Genentech/Roche and AstraZeneca.
- Business Wire•last month
Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting
First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session on Monday, June 3rd
- Simply Wall St.•last month
Seattle Genetics, Inc. (NASDAQ:SGEN): Financial Strength Analysis
With a market capitalization of US$11b, Seattle Genetics, Inc. (NASDAQ:SGEN) is a large-cap stock, which is considered...
- Business Wire•last month
Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference
Seattle Genetics, Inc. announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m.
- Business Wire•2 months ago
Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada
-Health Canada Approves ADCETRIS in Combination with AVD Chemotherapy for the Treatment of Previously Untreated Hodgkin Lymphoma Based on Positive Phase 3 ECHELON-1 Clinical Trial
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of SGEN earnings conference call or presentation 25-Apr-19 8:30pm GMT
Q1 2019 Seattle Genetics Inc Earnings Call
